Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $29.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Imunon in a research note on Thursday, December 19th.

Imunon Stock Up 10.0 %

Shares of IMNN stock opened at $0.89 on Thursday. The business has a 50 day moving average of $0.90 and a two-hundred day moving average of $0.94. The company has a market cap of $12.92 million, a P/E ratio of -0.47 and a beta of 2.03. Imunon has a 52 week low of $0.64 and a 52 week high of $3.65.

Institutional Investors Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC increased its holdings in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,505 shares of the company’s stock after buying an additional 13,570 shares during the quarter. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.